In February 2020, Chiesi founded Chiesi Global Rare Diseases, the Chiesi Farmaceutici Group’s business unit dedicated to developing therapies and solutions for people living with rare or ultrarare diseases. Based in Boston, Massachusetts, Chiesi Global Rare Diseases was established with the goal of addressing the still unmet needs of patients with rare conditions, which are often complex and difficult to diagnose.

The Chiesi Group commercializes medicines for the treatment of lysosomal storage disorders, such as Fabry disease, alphamannosidosis and nephropathic cystinosis; endometabolic diseases including homozygous familial hypercholesterolemia, lipodystrophy and acromegaly; as well as solutions for thalassemia, sickle cell disease, ADASCID, Leber’s Hereditary Optic Neuropathy (LHON), and epidermolysis bullosa.

Chiesi Pakistan has launched Ferriprox in the form of Oral solution 100mg/mL and Twice a Day tablets 1000mg for treatment of transfusional iron overload in the patients suffering from Thalassemia.

Rare Hematology

Thalassemia

Thalassemia is a rare, inherited blood disorder that impacts the body’s ability to produce hemoglobin and red blood cells. It can lead to progressive organ damage and other health problems.

Sickle Cell Disease

Sickle Cell Disease is an inherited blood disease in which the normally round red blood cells have an elongated “sickle” shape, resulting in a lack of blood flow that can cause organ damage. People with sickle cell are at increased risk of life-threatening complications that can require blood transfusions to manage disease complications.

Learn More About Sickle Cell Disease